nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—INSRR—salivary gland cancer	0.728	1	CbGaD
Crizotinib—LTK—tongue—salivary gland cancer	0.00247	0.0262	CbGeAlD
Crizotinib—EPHA4—tongue—salivary gland cancer	0.00136	0.0144	CbGeAlD
Crizotinib—MET—neck—salivary gland cancer	0.00129	0.0136	CbGeAlD
Crizotinib—NEK9—connective tissue—salivary gland cancer	0.00122	0.0129	CbGeAlD
Crizotinib—FES—parotid gland—salivary gland cancer	0.00111	0.0117	CbGeAlD
Crizotinib—SIK2—connective tissue—salivary gland cancer	0.0011	0.0116	CbGeAlD
Crizotinib—FES—saliva-secreting gland—salivary gland cancer	0.00106	0.0112	CbGeAlD
Crizotinib—IGF1R—neck—salivary gland cancer	0.00101	0.0107	CbGeAlD
Crizotinib—MAPK7—connective tissue—salivary gland cancer	0.000988	0.0104	CbGeAlD
Crizotinib—MET—connective tissue—salivary gland cancer	0.000925	0.00977	CbGeAlD
Crizotinib—CDK7—connective tissue—salivary gland cancer	0.000894	0.00945	CbGeAlD
Crizotinib—NEK9—lymphoid tissue—salivary gland cancer	0.000892	0.00943	CbGeAlD
Crizotinib—MET—epithelium—salivary gland cancer	0.000878	0.00928	CbGeAlD
Crizotinib—BMP2K—neck—salivary gland cancer	0.000846	0.00894	CbGeAlD
Crizotinib—JAK3—connective tissue—salivary gland cancer	0.000815	0.00862	CbGeAlD
Crizotinib—STK4—connective tissue—salivary gland cancer	0.0008	0.00846	CbGeAlD
Crizotinib—TESK1—parotid gland—salivary gland cancer	0.000776	0.00821	CbGeAlD
Crizotinib—TYRO3—connective tissue—salivary gland cancer	0.000756	0.00799	CbGeAlD
Crizotinib—ALK—connective tissue—salivary gland cancer	0.000756	0.00799	CbGeAlD
Crizotinib—BLK—lymphoid tissue—salivary gland cancer	0.000754	0.00797	CbGeAlD
Crizotinib—PTK2—neck—salivary gland cancer	0.000752	0.00795	CbGeAlD
Crizotinib—TBK1—neck—salivary gland cancer	0.000752	0.00795	CbGeAlD
Crizotinib—LYN—connective tissue—salivary gland cancer	0.000752	0.00795	CbGeAlD
Crizotinib—TESK1—saliva-secreting gland—salivary gland cancer	0.000744	0.00786	CbGeAlD
Crizotinib—NUAK2—parotid gland—salivary gland cancer	0.000736	0.00778	CbGeAlD
Crizotinib—ACVR1—parotid gland—salivary gland cancer	0.000731	0.00772	CbGeAlD
Crizotinib—IGF1R—connective tissue—salivary gland cancer	0.000727	0.00768	CbGeAlD
Crizotinib—RPS6KB1—neck—salivary gland cancer	0.000724	0.00765	CbGeAlD
Crizotinib—MAPK7—lymphoid tissue—salivary gland cancer	0.000722	0.00763	CbGeAlD
Crizotinib—TXK—lymphoid tissue—salivary gland cancer	0.000722	0.00763	CbGeAlD
Crizotinib—NUAK2—saliva-secreting gland—salivary gland cancer	0.000705	0.00745	CbGeAlD
Crizotinib—BMPR1B—epithelium—salivary gland cancer	0.000703	0.00744	CbGeAlD
Crizotinib—IKBKE—lymph node—salivary gland cancer	0.000702	0.00742	CbGeAlD
Crizotinib—ACVR1—saliva-secreting gland—salivary gland cancer	0.0007	0.0074	CbGeAlD
Crizotinib—IGF1R—epithelium—salivary gland cancer	0.00069	0.00729	CbGeAlD
Crizotinib—TESK1—connective tissue—salivary gland cancer	0.000683	0.00722	CbGeAlD
Crizotinib—MET—lymphoid tissue—salivary gland cancer	0.000676	0.00715	CbGeAlD
Crizotinib—TIE1—epithelium—salivary gland cancer	0.000671	0.00709	CbGeAlD
Crizotinib—RIPK2—parotid gland—salivary gland cancer	0.00066	0.00698	CbGeAlD
Crizotinib—CDK7—lymphoid tissue—salivary gland cancer	0.000654	0.00691	CbGeAlD
Crizotinib—FLT3—connective tissue—salivary gland cancer	0.000643	0.0068	CbGeAlD
Crizotinib—ACVR1—connective tissue—salivary gland cancer	0.000643	0.0068	CbGeAlD
Crizotinib—RIPK2—saliva-secreting gland—salivary gland cancer	0.000632	0.00668	CbGeAlD
Crizotinib—TBK1—parotid gland—salivary gland cancer	0.000613	0.00648	CbGeAlD
Crizotinib—TYK2—parotid gland—salivary gland cancer	0.000609	0.00643	CbGeAlD
Crizotinib—BMP2K—connective tissue—salivary gland cancer	0.000606	0.00641	CbGeAlD
Crizotinib—JAK3—lymphoid tissue—salivary gland cancer	0.000596	0.0063	CbGeAlD
Crizotinib—RPS6KB1—parotid gland—salivary gland cancer	0.00059	0.00623	CbGeAlD
Crizotinib—PLK4—lymphoid tissue—salivary gland cancer	0.000589	0.00622	CbGeAlD
Crizotinib—PTK2—saliva-secreting gland—salivary gland cancer	0.000587	0.0062	CbGeAlD
Crizotinib—TBK1—saliva-secreting gland—salivary gland cancer	0.000587	0.0062	CbGeAlD
Crizotinib—PTK2B—connective tissue—salivary gland cancer	0.000586	0.00619	CbGeAlD
Crizotinib—STK4—lymphoid tissue—salivary gland cancer	0.000585	0.00618	CbGeAlD
Crizotinib—TYK2—saliva-secreting gland—salivary gland cancer	0.000583	0.00616	CbGeAlD
Crizotinib—RIPK2—connective tissue—salivary gland cancer	0.000581	0.00614	CbGeAlD
Crizotinib—RPS6KB1—saliva-secreting gland—salivary gland cancer	0.000565	0.00597	CbGeAlD
Crizotinib—SLK—parotid gland—salivary gland cancer	0.000562	0.00594	CbGeAlD
Crizotinib—EPHB4—parotid gland—salivary gland cancer	0.000558	0.00589	CbGeAlD
Crizotinib—TYRO3—lymphoid tissue—salivary gland cancer	0.000553	0.00585	CbGeAlD
Crizotinib—FER—lymphoid tissue—salivary gland cancer	0.000553	0.00585	CbGeAlD
Crizotinib—ALK—lymphoid tissue—salivary gland cancer	0.000553	0.00585	CbGeAlD
Crizotinib—RIPK2—epithelium—salivary gland cancer	0.000551	0.00583	CbGeAlD
Crizotinib—MAP3K2—connective tissue—salivary gland cancer	0.000551	0.00582	CbGeAlD
Crizotinib—LYN—lymphoid tissue—salivary gland cancer	0.00055	0.00581	CbGeAlD
Crizotinib—EPHA2—parotid gland—salivary gland cancer	0.000547	0.00578	CbGeAlD
Crizotinib—MAP4K1—lymphoid tissue—salivary gland cancer	0.000542	0.00573	CbGeAlD
Crizotinib—PTK2—connective tissue—salivary gland cancer	0.000539	0.0057	CbGeAlD
Crizotinib—SLK—saliva-secreting gland—salivary gland cancer	0.000538	0.00569	CbGeAlD
Crizotinib—TYK2—connective tissue—salivary gland cancer	0.000536	0.00566	CbGeAlD
Crizotinib—EPHB4—saliva-secreting gland—salivary gland cancer	0.000534	0.00565	CbGeAlD
Crizotinib—MAP4K5—parotid gland—salivary gland cancer	0.000534	0.00564	CbGeAlD
Crizotinib—MAP3K3—parotid gland—salivary gland cancer	0.000534	0.00564	CbGeAlD
Crizotinib—IGF1R—lymphoid tissue—salivary gland cancer	0.000531	0.00562	CbGeAlD
Crizotinib—EPHA2—saliva-secreting gland—salivary gland cancer	0.000524	0.00554	CbGeAlD
Crizotinib—MAP4K2—lymphoid tissue—salivary gland cancer	0.000524	0.00554	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—salivary gland cancer	0.000519	0.00548	CbGeAlD
Crizotinib—AXL—connective tissue—salivary gland cancer	0.000514	0.00543	CbGeAlD
Crizotinib—PTK2—epithelium—salivary gland cancer	0.000512	0.00541	CbGeAlD
Crizotinib—MAP3K3—saliva-secreting gland—salivary gland cancer	0.000511	0.0054	CbGeAlD
Crizotinib—MAP4K5—saliva-secreting gland—salivary gland cancer	0.000511	0.0054	CbGeAlD
Crizotinib—EPHB6—parotid gland—salivary gland cancer	0.00051	0.00539	CbGeAlD
Crizotinib—AURKA—lymphoid tissue—salivary gland cancer	0.000504	0.00532	CbGeAlD
Crizotinib—NEK9—lymph node—salivary gland cancer	0.000503	0.00532	CbGeAlD
Crizotinib—YES1—parotid gland—salivary gland cancer	0.000493	0.00521	CbGeAlD
Crizotinib—RPS6KB1—epithelium—salivary gland cancer	0.000493	0.00521	CbGeAlD
Crizotinib—EPHB4—connective tissue—salivary gland cancer	0.000491	0.00519	CbGeAlD
Crizotinib—EPHB6—saliva-secreting gland—salivary gland cancer	0.000489	0.00516	CbGeAlD
Crizotinib—JAK2—connective tissue—salivary gland cancer	0.000487	0.00515	CbGeAlD
Crizotinib—TAOK3—parotid gland—salivary gland cancer	0.000487	0.00514	CbGeAlD
Crizotinib—MERTK—lymphoid tissue—salivary gland cancer	0.000486	0.00514	CbGeAlD
Crizotinib—LIMK2—lymphoid tissue—salivary gland cancer	0.000475	0.00502	CbGeAlD
Crizotinib—YES1—saliva-secreting gland—salivary gland cancer	0.000472	0.00499	CbGeAlD
Crizotinib—FLT3—lymphoid tissue—salivary gland cancer	0.00047	0.00497	CbGeAlD
Crizotinib—TEK—connective tissue—salivary gland cancer	0.00047	0.00496	CbGeAlD
Crizotinib—TAOK3—saliva-secreting gland—salivary gland cancer	0.000466	0.00493	CbGeAlD
Crizotinib—EPHB4—epithelium—salivary gland cancer	0.000466	0.00493	CbGeAlD
Crizotinib—JAK2—epithelium—salivary gland cancer	0.000463	0.00489	CbGeAlD
Crizotinib—PRKD1—lymph node—salivary gland cancer	0.000459	0.00485	CbGeAlD
Crizotinib—EPHA2—epithelium—salivary gland cancer	0.000457	0.00483	CbGeAlD
Crizotinib—LIMK1—lymph node—salivary gland cancer	0.000453	0.00478	CbGeAlD
Crizotinib—TEK—epithelium—salivary gland cancer	0.000446	0.00471	CbGeAlD
Crizotinib—PRKD3—lymph node—salivary gland cancer	0.000441	0.00466	CbGeAlD
Crizotinib—YES1—connective tissue—salivary gland cancer	0.000434	0.00459	CbGeAlD
Crizotinib—DSTYK—lymph node—salivary gland cancer	0.00043	0.00455	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—salivary gland cancer	0.000428	0.00453	CbGeAlD
Crizotinib—TAOK3—connective tissue—salivary gland cancer	0.000428	0.00453	CbGeAlD
Crizotinib—BLK—lymph node—salivary gland cancer	0.000425	0.0045	CbGeAlD
Crizotinib—LTK—lymph node—salivary gland cancer	0.000421	0.00445	CbGeAlD
Crizotinib—CASK—lymph node—salivary gland cancer	0.000421	0.00445	CbGeAlD
Crizotinib—SRC—connective tissue—salivary gland cancer	0.000417	0.00441	CbGeAlD
Crizotinib—MAPK7—lymph node—salivary gland cancer	0.000407	0.00431	CbGeAlD
Crizotinib—TXK—lymph node—salivary gland cancer	0.000407	0.00431	CbGeAlD
Crizotinib—FES—lymph node—salivary gland cancer	0.000403	0.00426	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—salivary gland cancer	0.000403	0.00426	CbGeAlD
Crizotinib—SRC—epithelium—salivary gland cancer	0.000396	0.00419	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—salivary gland cancer	0.000394	0.00417	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—salivary gland cancer	0.000394	0.00417	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—salivary gland cancer	0.000392	0.00414	CbGeAlD
Crizotinib—MET—lymph node—salivary gland cancer	0.000381	0.00403	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—salivary gland cancer	0.000379	0.00401	CbGeAlD
Crizotinib—FGR—lymphoid tissue—salivary gland cancer	0.000377	0.00399	CbGeAlD
Crizotinib—AXL—lymphoid tissue—salivary gland cancer	0.000376	0.00397	CbGeAlD
Crizotinib—CSF1R—connective tissue—salivary gland cancer	0.000375	0.00396	CbGeAlD
Crizotinib—CDK7—lymph node—salivary gland cancer	0.000369	0.0039	CbGeAlD
Crizotinib—TAOK2—lymph node—salivary gland cancer	0.000366	0.00387	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—salivary gland cancer	0.000356	0.00377	CbGeAlD
Crizotinib—EPHA3—lymph node—salivary gland cancer	0.000353	0.00373	CbGeAlD
Crizotinib—ACVR1B—lymph node—salivary gland cancer	0.000353	0.00373	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—salivary gland cancer	0.000352	0.00372	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—salivary gland cancer	0.000343	0.00363	CbGeAlD
Crizotinib—TEK—lymphoid tissue—salivary gland cancer	0.000343	0.00363	CbGeAlD
Crizotinib—ABL1—parotid gland—salivary gland cancer	0.000337	0.00356	CbGeAlD
Crizotinib—JAK3—lymph node—salivary gland cancer	0.000336	0.00355	CbGeAlD
Crizotinib—DCLK1—lymph node—salivary gland cancer	0.000334	0.00353	CbGeAlD
Crizotinib—PLK4—lymph node—salivary gland cancer	0.000332	0.00351	CbGeAlD
Crizotinib—STK4—lymph node—salivary gland cancer	0.00033	0.00349	CbGeAlD
Crizotinib—ABL1—saliva-secreting gland—salivary gland cancer	0.000322	0.00341	CbGeAlD
Crizotinib—YES1—lymphoid tissue—salivary gland cancer	0.000317	0.00335	CbGeAlD
Crizotinib—STK10—lymphoid tissue—salivary gland cancer	0.000314	0.00332	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—salivary gland cancer	0.000313	0.00331	CbGeAlD
Crizotinib—ALK—lymph node—salivary gland cancer	0.000312	0.0033	CbGeAlD
Crizotinib—FER—lymph node—salivary gland cancer	0.000312	0.0033	CbGeAlD
Crizotinib—TNK1—lymph node—salivary gland cancer	0.000309	0.00326	CbGeAlD
Crizotinib—BMPR1B—lymph node—salivary gland cancer	0.000306	0.00323	CbGeAlD
Crizotinib—MAP4K1—lymph node—salivary gland cancer	0.000306	0.00323	CbGeAlD
Crizotinib—SRC—lymphoid tissue—salivary gland cancer	0.000305	0.00323	CbGeAlD
Crizotinib—TNK2—lymph node—salivary gland cancer	0.0003	0.00317	CbGeAlD
Crizotinib—IGF1R—lymph node—salivary gland cancer	0.0003	0.00317	CbGeAlD
Crizotinib—ABL1—connective tissue—salivary gland cancer	0.000296	0.00313	CbGeAlD
Crizotinib—MAP4K2—lymph node—salivary gland cancer	0.000296	0.00312	CbGeAlD
Crizotinib—TIE1—lymph node—salivary gland cancer	0.000292	0.00308	CbGeAlD
Crizotinib—STK3—lymph node—salivary gland cancer	0.000292	0.00308	CbGeAlD
Crizotinib—AURKA—lymph node—salivary gland cancer	0.000284	0.003	CbGeAlD
Crizotinib—TESK1—lymph node—salivary gland cancer	0.000282	0.00298	CbGeAlD
Crizotinib—MERTK—lymph node—salivary gland cancer	0.000274	0.0029	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—salivary gland cancer	0.000274	0.0029	CbGeAlD
Crizotinib—LIMK2—lymph node—salivary gland cancer	0.000268	0.00283	CbGeAlD
Crizotinib—NUAK2—lymph node—salivary gland cancer	0.000267	0.00282	CbGeAlD
Crizotinib—MAP3K12—lymph node—salivary gland cancer	0.000265	0.0028	CbGeAlD
Crizotinib—FLT3—lymph node—salivary gland cancer	0.000265	0.0028	CbGeAlD
Crizotinib—ACVR1—lymph node—salivary gland cancer	0.000265	0.0028	CbGeAlD
Crizotinib—STK35—lymph node—salivary gland cancer	0.00026	0.00275	CbGeAlD
Crizotinib—ABL2—lymph node—salivary gland cancer	0.000253	0.00268	CbGeAlD
Crizotinib—BMP2K—lymph node—salivary gland cancer	0.00025	0.00264	CbGeAlD
Crizotinib—PTK2B—lymph node—salivary gland cancer	0.000242	0.00255	CbGeAlD
Crizotinib—RIPK2—lymph node—salivary gland cancer	0.00024	0.00253	CbGeAlD
Crizotinib—EPHA4—lymph node—salivary gland cancer	0.000232	0.00245	CbGeAlD
Crizotinib—MAP3K2—lymph node—salivary gland cancer	0.000227	0.0024	CbGeAlD
Crizotinib—PTK2—lymph node—salivary gland cancer	0.000222	0.00235	CbGeAlD
Crizotinib—TBK1—lymph node—salivary gland cancer	0.000222	0.00235	CbGeAlD
Crizotinib—TYK2—lymph node—salivary gland cancer	0.000221	0.00234	CbGeAlD
Crizotinib—IRAK1—lymph node—salivary gland cancer	0.000218	0.00231	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—salivary gland cancer	0.000217	0.00229	CbGeAlD
Crizotinib—RPS6KB1—lymph node—salivary gland cancer	0.000214	0.00226	CbGeAlD
Crizotinib—LCK—lymph node—salivary gland cancer	0.000213	0.00225	CbGeAlD
Crizotinib—FGR—lymph node—salivary gland cancer	0.000213	0.00225	CbGeAlD
Crizotinib—AXL—lymph node—salivary gland cancer	0.000212	0.00224	CbGeAlD
Crizotinib—SLK—lymph node—salivary gland cancer	0.000204	0.00216	CbGeAlD
Crizotinib—EPHB4—lymph node—salivary gland cancer	0.000202	0.00214	CbGeAlD
Crizotinib—JAK2—lymph node—salivary gland cancer	0.000201	0.00213	CbGeAlD
Crizotinib—EPHA2—lymph node—salivary gland cancer	0.000199	0.0021	CbGeAlD
Crizotinib—MAP3K3—lymph node—salivary gland cancer	0.000194	0.00205	CbGeAlD
Crizotinib—MAP4K5—lymph node—salivary gland cancer	0.000194	0.00205	CbGeAlD
Crizotinib—TEK—lymph node—salivary gland cancer	0.000194	0.00205	CbGeAlD
Crizotinib—EPHB6—lymph node—salivary gland cancer	0.000185	0.00196	CbGeAlD
Crizotinib—YES1—lymph node—salivary gland cancer	0.000179	0.00189	CbGeAlD
Crizotinib—STK10—lymph node—salivary gland cancer	0.000177	0.00187	CbGeAlD
Crizotinib—TAOK3—lymph node—salivary gland cancer	0.000177	0.00187	CbGeAlD
Crizotinib—SRC—lymph node—salivary gland cancer	0.000172	0.00182	CbGeAlD
Crizotinib—CSF1R—lymph node—salivary gland cancer	0.000155	0.00163	CbGeAlD
Crizotinib—ABL1—lymph node—salivary gland cancer	0.000122	0.00129	CbGeAlD
Crizotinib—ABCB1—epithelium—salivary gland cancer	8.74e-05	0.000924	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—salivary gland cancer	6.73e-05	0.000712	CbGeAlD
Crizotinib—ABCB1—lymph node—salivary gland cancer	3.8e-05	0.000402	CbGeAlD
Crizotinib—YES1—Signaling Pathways—NOTCH1—salivary gland cancer	2.98e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOTCH1—salivary gland cancer	2.97e-06	1.67e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—EP300—salivary gland cancer	2.94e-06	1.66e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—salivary gland cancer	2.92e-06	1.65e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JAG1—salivary gland cancer	2.92e-06	1.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CREBBP—salivary gland cancer	2.92e-06	1.64e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PYGB—salivary gland cancer	2.91e-06	1.64e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR4—salivary gland cancer	2.91e-06	1.64e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CCND1—salivary gland cancer	2.9e-06	1.63e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—salivary gland cancer	2.9e-06	1.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDH1—salivary gland cancer	2.9e-06	1.63e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EP300—salivary gland cancer	2.89e-06	1.63e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—salivary gland cancer	2.89e-06	1.63e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—HRAS—salivary gland cancer	2.87e-06	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FBXW7—salivary gland cancer	2.86e-06	1.61e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EP300—salivary gland cancer	2.85e-06	1.61e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—PTEN—salivary gland cancer	2.83e-06	1.6e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOTCH1—salivary gland cancer	2.83e-06	1.59e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HRAS—salivary gland cancer	2.83e-06	1.59e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—HRAS—salivary gland cancer	2.83e-06	1.59e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—HRAS—salivary gland cancer	2.81e-06	1.59e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MAP2K2—salivary gland cancer	2.81e-06	1.58e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	2.81e-06	1.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—PIK3CA—salivary gland cancer	2.8e-06	1.58e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PTEN—salivary gland cancer	2.8e-06	1.58e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HRAS—salivary gland cancer	2.8e-06	1.57e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—PTEN—salivary gland cancer	2.78e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—HRAS—salivary gland cancer	2.77e-06	1.56e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—HRAS—salivary gland cancer	2.76e-06	1.55e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PTEN—salivary gland cancer	2.75e-06	1.55e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOTCH1—salivary gland cancer	2.75e-06	1.55e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CREBBP—salivary gland cancer	2.74e-06	1.55e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—PIK3CA—salivary gland cancer	2.73e-06	1.54e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FOXO3—salivary gland cancer	2.73e-06	1.54e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—PIK3CA—salivary gland cancer	2.72e-06	1.53e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAP2K2—salivary gland cancer	2.71e-06	1.53e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	2.71e-06	1.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—salivary gland cancer	2.71e-06	1.53e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CREBBP—salivary gland cancer	2.7e-06	1.52e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EP300—salivary gland cancer	2.7e-06	1.52e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—PIK3CA—salivary gland cancer	2.7e-06	1.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CREBBP—salivary gland cancer	2.7e-06	1.52e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—PIK3CA—salivary gland cancer	2.69e-06	1.51e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—PIK3CA—salivary gland cancer	2.68e-06	1.51e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—PIK3CA—salivary gland cancer	2.67e-06	1.51e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EP300—salivary gland cancer	2.67e-06	1.5e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NUP62—salivary gland cancer	2.67e-06	1.5e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—PTEN—salivary gland cancer	2.67e-06	1.5e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—VCAN—salivary gland cancer	2.65e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EP300—salivary gland cancer	2.65e-06	1.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—HRAS—salivary gland cancer	2.65e-06	1.49e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—salivary gland cancer	2.64e-06	1.49e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—PIK3CA—salivary gland cancer	2.64e-06	1.49e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EP300—salivary gland cancer	2.62e-06	1.48e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—PIK3CA—salivary gland cancer	2.62e-06	1.48e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—PIK3CA—salivary gland cancer	2.61e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOTCH1—salivary gland cancer	2.6e-06	1.47e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—HRAS—salivary gland cancer	2.6e-06	1.46e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—PIK3CA—salivary gland cancer	2.59e-06	1.46e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—salivary gland cancer	2.59e-06	1.46e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCND1—salivary gland cancer	2.59e-06	1.46e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CREBBP—salivary gland cancer	2.57e-06	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CREBBP—salivary gland cancer	2.56e-06	1.44e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCND1—salivary gland cancer	2.55e-06	1.44e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAP2K2—salivary gland cancer	2.54e-06	1.43e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTEN—salivary gland cancer	2.54e-06	1.43e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDH1—salivary gland cancer	2.54e-06	1.43e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—salivary gland cancer	2.53e-06	1.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—PIK3CA—salivary gland cancer	2.53e-06	1.42e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—salivary gland cancer	2.52e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—salivary gland cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PTEN—salivary gland cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CREBBP—salivary gland cancer	2.49e-06	1.4e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—salivary gland cancer	2.48e-06	1.4e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—salivary gland cancer	2.48e-06	1.4e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—salivary gland cancer	2.47e-06	1.39e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PTEN—salivary gland cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—PIK3CA—salivary gland cancer	2.46e-06	1.38e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCND1—salivary gland cancer	2.44e-06	1.37e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—salivary gland cancer	2.44e-06	1.37e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—salivary gland cancer	2.42e-06	1.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EP300—salivary gland cancer	2.42e-06	1.36e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—salivary gland cancer	2.42e-06	1.36e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FOXO3—salivary gland cancer	2.41e-06	1.36e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—salivary gland cancer	2.4e-06	1.35e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EP300—salivary gland cancer	2.38e-06	1.34e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—salivary gland cancer	2.38e-06	1.34e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	2.37e-06	1.34e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCND1—salivary gland cancer	2.37e-06	1.33e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CREBBP—salivary gland cancer	2.36e-06	1.33e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PTEN—salivary gland cancer	2.35e-06	1.33e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EP300—salivary gland cancer	2.35e-06	1.32e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—salivary gland cancer	2.34e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOTCH1—salivary gland cancer	2.31e-06	1.3e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	2.28e-06	1.29e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PTEN—salivary gland cancer	2.28e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—salivary gland cancer	2.27e-06	1.28e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CREBBP—salivary gland cancer	2.26e-06	1.28e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDH1—salivary gland cancer	2.25e-06	1.27e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EP300—salivary gland cancer	2.25e-06	1.26e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—PTEN—salivary gland cancer	2.23e-06	1.26e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAP2K2—salivary gland cancer	2.23e-06	1.25e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOTCH1—salivary gland cancer	2.22e-06	1.25e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PTEN—salivary gland cancer	2.22e-06	1.25e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—PIK3CA—salivary gland cancer	2.21e-06	1.25e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	2.21e-06	1.25e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EP300—salivary gland cancer	2.18e-06	1.23e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—PIK3CA—salivary gland cancer	2.17e-06	1.23e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—PIK3CA—salivary gland cancer	2.14e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EP300—salivary gland cancer	2.12e-06	1.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—PIK3CA—salivary gland cancer	2.12e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—PIK3CA—salivary gland cancer	2.12e-06	1.2e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EP300—salivary gland cancer	2.11e-06	1.19e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—PIK3CA—salivary gland cancer	2.11e-06	1.19e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—salivary gland cancer	2.1e-06	1.19e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CREBBP—salivary gland cancer	2.09e-06	1.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PTEN—salivary gland cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOTCH1—salivary gland cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AQP1—salivary gland cancer	2.07e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—salivary gland cancer	2.05e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—salivary gland cancer	2.05e-06	1.15e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—salivary gland cancer	2.03e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CREBBP—salivary gland cancer	2.02e-06	1.14e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—salivary gland cancer	2.01e-06	1.13e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—salivary gland cancer	2e-06	1.13e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—PIK3CA—salivary gland cancer	2e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—salivary gland cancer	1.99e-06	1.12e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—salivary gland cancer	1.98e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PIK3CA—salivary gland cancer	1.98e-06	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAP2K2—salivary gland cancer	1.97e-06	1.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—salivary gland cancer	1.97e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—salivary gland cancer	1.96e-06	1.11e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTEN—salivary gland cancer	1.96e-06	1.1e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—PIK3CA—salivary gland cancer	1.96e-06	1.1e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—salivary gland cancer	1.95e-06	1.1e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PIK3CA—salivary gland cancer	1.94e-06	1.09e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTEN—salivary gland cancer	1.93e-06	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTEN—salivary gland cancer	1.92e-06	1.08e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—salivary gland cancer	1.91e-06	1.08e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—salivary gland cancer	1.9e-06	1.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CREBBP—salivary gland cancer	1.89e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—PIK3CA—salivary gland cancer	1.88e-06	1.06e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—salivary gland cancer	1.87e-06	1.05e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—salivary gland cancer	1.85e-06	1.04e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—salivary gland cancer	1.84e-06	1.04e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—salivary gland cancer	1.84e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—salivary gland cancer	1.84e-06	1.03e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTEN—salivary gland cancer	1.83e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—salivary gland cancer	1.83e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTEN—salivary gland cancer	1.83e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOTCH1—salivary gland cancer	1.82e-06	1.03e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—salivary gland cancer	1.81e-06	1.02e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—salivary gland cancer	1.8e-06	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PIK3CA—salivary gland cancer	1.79e-06	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—salivary gland cancer	1.78e-06	1e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PIK3CA—salivary gland cancer	1.77e-06	9.99e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PIK3CA—salivary gland cancer	1.76e-06	9.92e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—salivary gland cancer	1.75e-06	9.84e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—salivary gland cancer	1.74e-06	9.81e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—salivary gland cancer	1.74e-06	9.8e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PIK3CA—salivary gland cancer	1.74e-06	9.78e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—salivary gland cancer	1.7e-06	9.6e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—salivary gland cancer	1.7e-06	9.56e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—salivary gland cancer	1.69e-06	9.5e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—salivary gland cancer	1.68e-06	9.46e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—salivary gland cancer	1.66e-06	9.36e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—salivary gland cancer	1.66e-06	9.34e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CREBBP—salivary gland cancer	1.65e-06	9.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NUP62—salivary gland cancer	1.65e-06	9.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—VCAN—salivary gland cancer	1.63e-06	9.2e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—salivary gland cancer	1.63e-06	9.18e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—salivary gland cancer	1.62e-06	9.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH1—salivary gland cancer	1.61e-06	9.09e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—salivary gland cancer	1.61e-06	9.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—salivary gland cancer	1.61e-06	9.07e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—salivary gland cancer	1.61e-06	9.06e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—salivary gland cancer	1.61e-06	9.05e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—salivary gland cancer	1.61e-06	9.05e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—salivary gland cancer	1.57e-06	8.85e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—salivary gland cancer	1.56e-06	8.81e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—salivary gland cancer	1.56e-06	8.78e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—salivary gland cancer	1.54e-06	8.69e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—salivary gland cancer	1.54e-06	8.66e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—salivary gland cancer	1.49e-06	8.41e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—salivary gland cancer	1.49e-06	8.41e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—salivary gland cancer	1.49e-06	8.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—salivary gland cancer	1.49e-06	8.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—salivary gland cancer	1.47e-06	8.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREBBP—salivary gland cancer	1.46e-06	8.24e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—salivary gland cancer	1.45e-06	8.19e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—salivary gland cancer	1.45e-06	8.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—salivary gland cancer	1.44e-06	8.11e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—salivary gland cancer	1.42e-06	8.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—salivary gland cancer	1.4e-06	7.87e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—salivary gland cancer	1.38e-06	7.78e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—salivary gland cancer	1.37e-06	7.74e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CREBBP—salivary gland cancer	1.37e-06	7.73e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—salivary gland cancer	1.36e-06	7.68e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—salivary gland cancer	1.36e-06	7.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—salivary gland cancer	1.36e-06	7.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—salivary gland cancer	1.35e-06	7.59e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—salivary gland cancer	1.34e-06	7.53e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—salivary gland cancer	1.32e-06	7.43e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—salivary gland cancer	1.29e-06	7.28e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—salivary gland cancer	1.29e-06	7.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—salivary gland cancer	1.29e-06	7.24e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—salivary gland cancer	1.28e-06	7.2e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—salivary gland cancer	1.26e-06	7.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—salivary gland cancer	1.26e-06	7.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—salivary gland cancer	1.25e-06	7.07e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—salivary gland cancer	1.25e-06	7.04e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—salivary gland cancer	1.22e-06	6.89e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—salivary gland cancer	1.21e-06	6.84e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—salivary gland cancer	1.2e-06	6.74e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—salivary gland cancer	1.19e-06	6.71e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—salivary gland cancer	1.19e-06	6.7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—salivary gland cancer	1.18e-06	6.65e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—salivary gland cancer	1.16e-06	6.54e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—salivary gland cancer	1.14e-06	6.42e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—salivary gland cancer	1.13e-06	6.34e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—salivary gland cancer	1.1e-06	6.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—salivary gland cancer	1.08e-06	6.1e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—salivary gland cancer	1.06e-06	5.94e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—salivary gland cancer	1.05e-06	5.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—salivary gland cancer	1.05e-06	5.89e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CREBBP—salivary gland cancer	1.04e-06	5.83e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—salivary gland cancer	1.02e-06	5.72e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—salivary gland cancer	9.97e-07	5.62e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—salivary gland cancer	9.83e-07	5.54e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—salivary gland cancer	9.8e-07	5.52e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—salivary gland cancer	9.74e-07	5.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—salivary gland cancer	9.51e-07	5.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—salivary gland cancer	9.4e-07	5.3e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—salivary gland cancer	9.35e-07	5.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—salivary gland cancer	9.2e-07	5.18e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—salivary gland cancer	8.8e-07	4.96e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—salivary gland cancer	8.33e-07	4.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—salivary gland cancer	8.06e-07	4.54e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—salivary gland cancer	7.71e-07	4.34e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—salivary gland cancer	7.4e-07	4.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—salivary gland cancer	7.37e-07	4.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—salivary gland cancer	7.13e-07	4.02e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—salivary gland cancer	7.05e-07	3.97e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—salivary gland cancer	6.91e-07	3.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—salivary gland cancer	6.82e-07	3.84e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	6.38e-07	3.59e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	5.22e-07	2.94e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—salivary gland cancer	4.56e-07	2.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—salivary gland cancer	4.35e-07	2.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	3.21e-07	1.81e-06	CbGpPWpGaD
